Nile Therapeutics, Inc.

Nile Therapeutics is a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular disease and other areas of unmet medical need.

CD-NP is a novel rationally designed chimeric natriuretic peptide in clinical studies for an initial indication of acute decompensated heart failure. » More

» Corporate Fact Sheet

August 16, 2010 - Nile Therapeutics Reports 2010 Second Quarter Financial Results » Read

July 22, 2010 - Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors » Read

July 6, 2010 - Nile Therapeutics Completes Dosing of Phase II Study » Read

Interested investors or potential investors may conveniently receive E-mail alert messages whenever certain new company information is posted to this site. To automatically receive Nile Therapeutics, Inc. e-mail alerts, enter your e-mail address and click on the Subscribe button.